Welcome to this special edition magazine created in collaboration between International Clinical Trials and Trilogy Writing & Consulting, an Indegene Company. This magazine explores how artificial intelligence (AI) is reshaping the medical writing domain – from clinical trial transparency, patient privacy, ethical considerations to the evolving skill set of tomorrow’s medical writers.   

As of 2026, AI has officially moved from ‘interesting buzzword’ to ‘daily companion’. Medical writers across the globe are asking: What will this mean for our profession? Our ethics? Our patients? Our future skills?   

Whether one is navigating change management or preparing for the next generation of tools, we envision this magazine to be an essential guide to understanding where we are now and what lies ahead. 

Trilogy’s Senior Partner Lisa Chamberlain James, Chief Editor of this magazine, sets the stage for a collection of real world insights from leading voices at American Medical Writers Association (AMWA) AI Task Force, AstraZeneca, Bayer, European Medical Writers Association (EMWA) AI Working Group, Holtzople Consulting, Indegene, the Patient Information Forum (PIF), Pfizer, The Spark Global, and Trilogy. 

You can read the magazine here.